Single pivotal trial now the default for full drug approval?

What does our CEO Carsten Faltum think about the FDA’s new stance that a single pivotal trial is now the default for full drug approval?

Click below to see what Carsten discussed with BioSpace - what this means for drug development, why trial design quality matters more than ever and how Celex Oncology Innovations Ltd’s pancreatic cancer programme was built around this approach from the outset.

Read his perspective in full in BIOSPACE